<DOC>
	<DOCNO>NCT00870571</DOCNO>
	<brief_summary>The purpose study ass single-dose relative bioavailability Actavis Group hf Pfizer ( Norvasc® ) 10 mg amlodipine besylate tablet , fed condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , 2-period , 2-sequence , crossover design . Official Title : Comparative , Randomized , Single-Dose , 2-way Crossover Bioavailability Study Actavis Group hf Pfizer Inc. ( Norvasc® ) 10 mg Amlodipine Besylate Tablets Healthy Adult Volunteers FedConditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Subject candidate must fulfill follow inclusion criterion eligible participation study , unless otherwise specify : Healthy adult male female volunteer , 1855 year age ; Subject nonsmoker moderate smoker ( less 10 cigarette day ) least 3 month . Weighing least 60 kg male 52 kg female within 15 % ideal weight ( Table `` Desirable Weights Adults '' , Metropolitan Life Insurance Company , 1983 ) ; Medically healthy subject clinically normal laboratory profile . vital sign ECGs ; Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose , throughout study 14 day follow last dose use one follow acceptable birth control method : 1. surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum . 2 . IUD place least 3 month . 3. barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose , throughout study , 14 day follow last dose . 4. surgical sterilization partner ( vasectomy 6 month minimum ) . 5. hormonal contraceptive least 3 month prior first dose study 14 day follow last dose . Other birth control method may deem acceptable . Postmenopausal woman amenorrhea least 2 year eligible . Give voluntary write informed consent participate study . Subject candidate must enrol study meet follow criterion : History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : alcoholism drug abuse within past year ; hypersensitivity idiosyncratic reaction amlodipine calcium channel blocker . Female subject pregnant lactating . SUbjects test positive screening HIV , HbsAg HeV . Subjects whose sit blood pressure le 110/60 mmHg screen 100/55 mmHg dose . Subjects whose pulse low 55 b.p.m . screen 50 b.p.m . prior dosing . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know cytochrome P450 enzyme ) within 10 day prior first dose . Subjects use drug substance know strong inducer CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Subjects , completion study , would donate excess : 500 mL blood In 14 day ; 1500 mL blood 160 day ; 2500 mL blood In 1 year . Subjects participate another clinical trial within 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>amlodipine besylate</keyword>
	<keyword>amlodipine</keyword>
	<keyword>Healthy subject</keyword>
</DOC>